SenzaGen establishes subsidiary in the US
To quickly strengthen its commercial presence in the US market, Swedish SenzaGen AB expands globally and establishes a subsidiary in California.
To quickly strengthen its commercial presence in the US market, Swedish SenzaGen AB expands globally and establishes a subsidiary in California.
DAVIS, Calif., March 14, 2016 /PRNewswire/ -- SenzaGen, which develops and implements non-animal allergy tests of chemicals and proteins for the chemical, pharmaceutical and cosmetic industries, expands its sales organization and prepares the company for an IPO in 2017. Senzagen, a Lund University Department of Immunotechnology spin-out was recently recognized as one of Sweden's most promising young and innovative companies.
Responsible for Senzagen's US operations will be toxicologist Dr. Brian Rogers as US CEO, and Head of business development will be immunologist Dr. Sandra Reynoso.
For more information, please contact:
Anki Malmborg Hager, Ph D, CEO,
E-mail: [email protected]
SE: +46 768 284822
US: +1 530 867 5600
About SenzaGen
SenzaGen provides in vitro dermal and respiratory testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company's unique test GARD is based on research from the Department of Immunotechnology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.
About GARD
By analyzing 200 and 389 genomic markers, depending on the test, instead of 1-2 markers as competing methods, GARD delivers results with 90 % accuracy. This can be compared to the golden standard, animal tests on mice, that provide 72 % accuracy. SenzaGen's test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance cause allergy.
Logo - http://photos.prnewswire.com/prnh/20160314/343964LOGO
SOURCE SenzaGen
Share this article